血清胸腺因子(FTS)的抗肿瘤作用  

The anticancer effect of serum thymic factor(FTS)

作　　者：张长平[1] 乐嘉静[2] 李湛君[2] 李庆平[1] 徐康森[2] 

机构地区：[1]南京医科大学,南京210029 [2]中国药品生物制品检定所,北京100050

出　　处：《药物分析杂志》2007年第6期860-862,共3页Chinese Journal of Pharmaceutical Analysis

摘　　要：目的:观察血清胸腺因子(FTS)对人肝癌细胞的抑制作用。方法:裸鼠皮下接种人肝癌细胞 Hepg-2,待肿瘤生长后连续皮下注射不同剂量的 FTS,测定其抑瘤率;并测定 T 细胞增殖能力、吞噬指数(PI)等免疫指标。结果:荷瘤裸鼠皮下注射高、中剂量后抑瘤率均大于30%,且与对照组(NS)有显著性差异(p<0.01),低剂量组与 NS 组无显著性差异。另外 ConA 刺激后0.016 mg·mL^(-1)处刺激指数(SI)最大,FTS 组 PI 明显大于 NS 组。结论:FIS 对人肝癌细胞 Hepg-2有抑瘤作用且增强其免疫功能。Objective： To study the inhibitory effect of serum thymic factor （FTS） on cancer cells. Method： Bearing cancer nude mice were administrated FTS. Inhibitory rate were determined. Stimulation index （SI） and phagocytic index （PI） were determined,too. Results ：Inhibitory rate exceeded 30% in high dose group and middle dose group in nude mice. After ConA stimulated, SI achieved maximum at 0. 016 mg· mL^-1. PI were about 2 times as much as the control. Conclusion： FTS shows significant suppressing action on the growth of human liver cancer cells and it enhances the immunology activity of the organism.

关 键 词：血清胸腺因子(FTS) 肝癌细胞 抑瘤作用 免疫增强 

分 类 号：R917[医药卫生—药物分析学]